Dosage guide · 10 mg vial

Kisspeptin Dosage Protocol

Kisspeptin-10 (metastin) · reproductive neuroendocrine peptide

The reference protocol uses 100 mcg once daily for weeks 1–2, then 200 mcg once daily. With 3 mL of bacteriostatic water, a 10 mg vial is 3.33 mg/mL, so 100 mcg measures 3 units (0.03 mL) on a U-100 syringe.

How oftenOnce daily

Starting dose100 mcg

Start = units3 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Kisspeptin 10 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Kisspeptin References

01 · DOSAGE CHART

Kisspeptin dosage chart

Gradual daily approach · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the mix used by the attributed 10 mg reference protocol, giving 3.33 mg/mL.

Kisspeptin dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units	Syringe fill
Weeks 1–2Start	100 mcg	3 units0.03 mL
Week 3 onwardsMaintenance	200 mcg	6 units0.06 mL

Once daily · any consistent time · subcutaneous injection

The attributed reference protocol steps from 100 mcg daily to 200 mcg daily after 2 weeks.

Its stated timeframe is 8–12 weeks.

Community-reported subcutaneous amounts — Kisspeptin-10 has no approved or clinically established subcutaneous dose. Education only, not medical advice. Dose amounts adapted from Kisspeptin 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

1Kisspeptin 10 mg vial9.8 mg needed in total

571 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle3 mL used for mixing

114Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.030 mL

Equivalent U-100 volume scale position

3markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Kisspeptin

Protocol overview

Starting dose: 100 mcg once daily for 2 weeks
How it increases: 200 mcg once daily from week 3
Frequency: Once daily
When to take it: Any consistent time of day
Cycle length: 8–12 weeks in the attributed reference protocol
Common mix: 3 mL BAC water → 3.33 mg/mL

Storage

Before mixing: The attributed protocol says to keep lyophilised powder frozen at −20 °C, dry and away from light.
After mixing: The attributed protocol says to refrigerate reconstituted material at 2–8 °C, protected from light.
Never: Avoid repeated freeze–thaw cycles or using material that is cloudy or has particles.

How it works

Kisspeptin-10, also called metastin, is the 10-amino-acid active sequence shared by the kisspeptin family. It activates the KISS1R receptor and is understood to stimulate hypothalamic GnRH release, followed by pituitary LH and FSH release.

Human hormonal responses are sex- and cycle-stage-dependent. In one experiment, intravenous Kisspeptin-10 stimulated gonadotropins in men and in preovulatory women, but subcutaneous Kisspeptin-10 did not change reproductive hormones in healthy women in the follicular phase.

Illustrated mechanism explainer

What the research shows

In six healthy men, intravenous bolus Kisspeptin-10 from 0.01 to 3 micrograms/kg produced a dose-dependent LH response; the 1 microgram/kg dose increased mean LH from 4.1 to 12.4 IU/L at 30 minutes.
In four healthy men, a 22.5-hour intravenous infusion at 4 micrograms/kg/hour increased mean LH from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L.
A study enrolling 35 healthy women and 11 healthy men found no gonadotropin change in follicular-phase women after subcutaneous Kisspeptin-10 up to 32 nmol/kg, while 10 nmol/kg intravenously increased LH and FSH in preovulatory women.
A completed ClinicalTrials.gov record in hypogonadotropic hypogonadism enrolled 18 participants and used 20 intravenous Kisspeptin-10 boluses over 40 hours under inpatient monitoring.
Kisspeptin-10 is not an approved medicine in Australia. The TGA identifies the ARTG as the public register of therapeutic goods approved for supply; no Kisspeptin-10 ARTG medicine entry was identified in the sources checked.

Reported side effects

Human Kisspeptin-10 evidence is limited to small, closely monitored research groups and cannot establish the safety of unregulated subcutaneous products.
In the first human Kisspeptin-10 experiment in six men, blood pressure, heart rate, oxygen saturation, blood counts, renal tests and liver tests remained stable, and no adverse events were reported.
Kisspeptin-10 changes GnRH, LH, FSH and sex-hormone signalling. Hormonal responses differed by sex and menstrual-cycle stage in human research.
The short plasma half-life reported after intravenous administration was about 4 minutes, so findings from monitored intravenous experiments cannot be assumed to apply to a subcutaneous vial protocol.

Important notes

Kisspeptin-10 is not an approved medicine in Australia and this unstocked 10 mg vial is a research reference, not a substitute for medical care.
Hormonal effects can affect reproductive function. Anyone with fertility, menstrual, testosterone or other endocrine concerns should involve an appropriate clinician.
Prohibited in sport at all times: the 2026 WADA Prohibited List places kisspeptin and its agonist analogues in S2 peptide hormones and releasing factors.
Published Kisspeptin-10 human experiments used supervised, weight-based intravenous doses; they do not validate this community-reported daily subcutaneous schedule.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS